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Prevention of neonatal oxygen-induced brain damage
by reduction of intrinsic apoptosis
M Sifringer*,1,2,7, I Bendix3,7, C Bo¨rner2, S Endesfelder2, C von Haefen1, A Kalb1, S Holifanjaniaina4,5, S Prager3, GW Schlager3,
M Keller3, E Jacotot4,5,6 and U Felderhoff-Mueser3
Within the last decade, it became clear that oxygen contributes to the pathogenesis of neonatal brain damage, leading to
neurocognitive impairment of prematurely born infants in later life. Recently, we have identified a critical role for receptor-
mediated neuronal apoptosis in the immature rodent brain. However, the contribution of the intrinsic apoptotic pathway
accompanied by activation of caspase-2 under hyperoxic conditions in the neonatal brain still remains elusive. Inhibition of
caspases appears a promising strategy for neuroprotection. In order to assess the influence of specific caspases on
the developing brain, we applied a recently developed pentapeptide-based group II caspase inhibitor (5-(2,6-difluoro-
phenoxy)-3(R,S)-(2(S)-(2(S)-(3-methoxycarbonyl-2(S)-(3-methyl-2(S)-((quinoline-2-carbonyl)-amino)-butyrylamino)propionylamino)
3-methylbutyrylamino)propionylamino)-4-oxo-pentanoic acid methyl ester; TRP601). Here, we report that elevated oxygen
(hyperoxia) triggers a marked increase in active caspase-2 expression, resulting in an initiation of the intrinsic apoptotic pathway
with upregulation of key proteins, namely, cytochrome c, apoptosis protease-activating factor-1, and the caspase-independent
protein apoptosis-inducing factor, whereas BH3-interacting domain death agonist and the anti-apoptotic protein B-cell
lymphoma-2 are downregulated. These results coincide with an upregulation of caspase-3 activity and marked
neurodegeneration. However, single treatment with TRP601 at the beginning of hyperoxia reversed the detrimental effects in
this model. Hyperoxia-mediated neurodegeneration is supported by intrinsic apoptosis, suggesting that the development of
highly selective caspase inhibitors will represent a potential useful therapeutic strategy in prematurely born infants.
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The number of infants born prematurely has substantially
increased in the last two decades, with a worldwide rate of
9.6%. Substantial neurological morbidity may occur in survivors
of preterm birth.1,2 In recent years, experimental studies
revealed that oxygen, which is widely used in neonatal intensive
care to treat respiratory distress, triggers a disruption of
intracellular redox homeostasis. This disturbance can lead to
oxidative and nitrative stress, resulting in increased neuronal
and oligodendroglial apoptosis in the developing brain.3–5
Apoptosis is the major type of cell death involved in
development and tissue homeostasis to build up and maintain
structural and functional organs. It is an important mechanism
that determines the size, shape, and function of the vertebrate
nervous system.6 Two main pathways have a key role in the
apoptotic program, namely, extrinsic and intrinsic apoptosis,
which finally activate executioner caspases such as
caspase-3, leading to characteristic features of this type of
cell death, such as cell shrinkage, membrane blebbing,
chromatin condensation, and DNA fragmentation.7
The extrinsic pathway is initiated by ligand-induced activa-
tion of specific death receptors of the tumor necrosis factor
(TNF) superfamily, such as Fas, TNFR or TNF-related
apoptosis-inducing ligand (TRAIL) at the plasma membrane.7
There is a growing body of evidence that in the immature
brain, Fas-dependent apoptosis is involved in experimental
models of neonatal brain injury, such as hypoxia-ischemia,8
infant head trauma,9 and, as recently observed, after
hyperoxic conditions.10
The second apoptotic pathway is mediated by intrinsic
stress signals, such as DNA damage, oxidative stress or
growth factor deprivation, and is characterized by the
involvement of mitochondria.7,11 Such stimuli induce the
release of cytochrome c from the inner mitochondrial
membrane into the cytosol. This release of cytochrome c is
believed to be mediated by members of the pro-apoptotic
B-cell lymphoma-2 (Bcl-2) family, such as Bcl-2-associated
X protein (Bax), which is indispensable in the intrinsic
apoptotic pathway. After a death signal, Bax activation,
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mediated by truncated Bcl-2 homology 3 (BH3)-only protein
as BH3-interacting domain death agonist (Bid), leads to
oligomerization and insertion to the lipid bilayer of the
mitochondrial outer membrane, thereby initiating a channel-
like structure that causes mitochondrial outer membrane
permeabilization (MOMP), resulting in cytochrome
c release.12 Cytosolic cytochrome c binds to apoptosis
protease-activating factor-1 (Apaf-1), and in the presence of
ATP/dATP such complexes, which are called apoptosomes,
can recruit and activate pro-caspase-9, leading to subsequent
effector caspase (mostly caspase-3) activation that triggers
apoptosis.13 Through MOMP not only caspase-dependent but
also caspase-independent apoptosis is initiated.14 Apoptosis-
inducing factor (AIF) was the first discovered protein that
regulates caspase-independent apoptosis.15 It was demon-
strated that AIF is proteolytically released from mitochondria
to the cytosol. Once in the cytosol, AIF translocates to the
nucleus where it contributes to apoptosis.16
Although being one of the first discovered and most
conserved caspases across mammalians, the function of
caspase-2 in apoptosis as an initiator or an executioner
caspase has remained enigmatic for a long time.17 However, it
was demonstrated that caspase-2 is an initiator caspase
involved in MOMP during apoptosis induced by several
cellular insults, including heat shock, DNA damage, mito-
chondria oxidative stress, and cytoskeletal disruption.18–20
We investigated the effect of hyperoxia on the intrinsic
apoptotic cascade by evaluating the expression of cyto-
chrome c, Apaf-1, Bid, caspase-2, -3, the anti-apoptotic
molecule Bcl-2. Additionally, we demonstrate that TRP601
(5-(2,6-difluoro-phenoxy)-3(R,S)-(2(S)-(2(S)-(3-methoxycarbo-
nyl-2(S)-(3-methyl-2(S)-((quinoline-2-carbonyl)-amino)-butyryl-
amino)propionylamino)3-methylbutyrylamino)propionylamino)-
4-oxo-pentanoic acid methyl ester), a pentapeptide-based
caspase-2/caspase-3 inhibitor, which was recently published
to protect the neonatal rodent brain against excitotoxicity,
hypoxia–ischemia, and perinatal arterial stroke,21 has a
protective role in the context of hyperoxia. Furthermore, we
provide evidence that hyperoxia triggers caspase-indepen-
dent apoptosis by regulating AIF expression in vivo, which is
also affected by TRP601.
Results
Hyperoxia mediates caspase-2 and -3 activation that is
reduced by TRP601. Using a preferential caspase-8
inhibitor, we have previously shown that caspase-8 is
critically involved in Fas-mediated ‘extrinsic’ neuronal
apoptosis after neonatal hyperoxia treatment.10 To test
whether the ‘intrinsic’ apoptotic pathway, suggested to be
facilitated by caspase-2,20,22 might also contribute to
hyperoxia-mediated neonatal brain injury, we made use of
a new pentapeptide caspase inhibitor designed to be a
competitive and irreversible inhibitor (TRP601). Therefore,
we performed initial in vitro experiments to determine the
inhibitory capacity and specificity of TRP601. As shown in
Figure 1a, TRP601 inhibits recombinant caspase-2 and -3
(Figure 1a). It should be noted that TRP601 is a pentapeptide
derivative containing 2 methyl ester (OMe) groups on the
lateral chains of P1 and P4 aspartyl residues. As blood and
cytoplasm of cells contain active esterase, these OMe
groups of TRP601 are progressively removed after in vivo
administration. We have synthesized this major metabolite
(D2Me-TRP601) and evaluated its caspase-inhibitory
capacity against recombinant caspase-2 and -3. Interes-
tingly, D2Me-TRP601 is a very potent caspase-2 and -3
inhibitor (IC50/D2MeTRP601/Casp2B7.4nM; IC50/D2MeTRP601/Casp3
B0.4nM; Figure 1b).
To characterize the functional consequences of inhibition
by TRP601 in vivo, we determined cleaved caspase-2
expression and the enzymatic activity of caspase-2 and -3 in
thalamic tissue. According to previous observations,10,23 we
detected an increase of caspase-3 activity, one of the main
executioner caspases, in oxygen treated six-day-old rats after
12 h (186%) that peaks after 24 h (301%) of hyperoxia and that
was ameliorated by TRP601 treatment (128% and 186%,
respectively, Figure 1c). Of note, as revealed by protein
expression of processed caspase-2 and enzymatic activity,
compared with caspase-3, an even more significant increase
was noted after 12 or 24 h of hyperoxia (364% and 649%,
respectively, Figure 1d; 358% and 677%, respectively,
Figure 1e, black bars), which was strongly reduced by
TRP601 treatment (148% and 209%, respectively,
Figure 1d; 125% and 250%, respectively, Figure 1e, gray
bars), whereas TRP601 had no significant effect under
normoxic conditions (dashed bars, Figure 1c–e).
TRP601 attenuates neuronal cell death in the developing
brain. In line with the results of caspase-2 and -3 under
hyperoxic conditions, neuronal cell death was significantly
reduced after TRP601 treatment in cortex (frontal (II and IV),
parietal (II and IV), cingulate (II and IV), and retrosplenial
(II and IV)), caudate nucleus, corpus callosum and adjacent
white matter, thalamus (laterodorsal, mediodorsal, and
ventral nuclei), hippocampal dentate gyrus, and subiculum
of rats treated for 24 h with 80% oxygen, as revealed by
histological examination of Fluoro-Jade B-positive cells in 16
brain regions (Figure 2). The application of TRP601 under
control conditions did not influence levels of physiological
apoptosis (dashed versus white bar).
Hyperoxia operates via intrinsic apoptosis in the
developing rat brain. As oxidative stress is one of the
major causes of increased neural apoptosis in the developing
brain under hyperoxic conditions,3,4,10,23,24 we were
interested in the regulation of protein expression of specific
signaling molecules that are part of the mitochondria-
dependent ‘intrinsic’ apoptotic pathway. These signaling
pathway culminate in MOMP, and several previous studies
have suggested that caspase-2 acts upstream of and
initiating MOMP by direct processing of full-length Bid to
activated truncated tBid.17
In this model, the analysis of full-length Bid in thalamic
protein fraction by immunoblotting revealed a significant
reduction of Bid after 12 and 24 h hyperoxia, suggesting a
cleavage and subsequent activation of Bid (tBid), thereby
providing a strong hint to the involvement of the intrinsic
apoptotic pathway (Figure 3, black bars). Note, single
application of the caspase-modulating agent (TRP601)
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restores nonactivated Bid in the cytosol (Figure 3, gray bars),
the application of TRP601 generates no change under room
air (normoxia, Figure 3, dashed bar). Furthermore, isolation of
mitochondria and cytosolic protein fractions from six- to
seven-day-old rat pups and subsequent western blot analysis
showed that under hyperoxic conditions cytosolic cytochrome c
is increased, whereas it is decreased in mitochondria. The
in vivo treatment with TRP601 reversed these hyperoxia-
induced changes in subcellular cytochrome c distribution
(Figure 4a). Densitometric analysis revealed highly significant
differences in the hyperoxic and the treatment groups in both
cellular fractions, whereas cytochrome c expression remains
Figure 1 Dose–response plots for inhibition of caspase-2 and -3 with TRP601 and its active metabolite. TRP601 (a) and D2Me-TRP601 (b) were added to recombinant
caspase-2 (gray curves) and caspase-3 (black curves) to determine initial enzyme velocity and IC50 values in chromogenic microplate assay. TRP601 and D2Me-TRP601
were added simultaneously to substrates (plain curves; IC50/TRP601/Casp3¼ 25.58±3.1 nM; IC50/D2Me-TRP601/Casp3¼ 0.39±0.11 nM; IC50/TRP601/Casp2(a)¼ 471.8±91.3 nM;
IC50/D2Me-TRP601/Casp2(a)¼ 7.4±3.18 nM) or alternatively 45 min before substrates (dotted curves; IC50/TRP601/Casp2(b)¼ 115.2±39.12 nM; IC50/D2Me-TRP601/
Casp2(b)¼ 2.67±1.46 nM). (c) Six-day-old Wistar rat pups were either injected with the caspase inhibitor TRP601 (1 mg/kg bodyweight, i.p.) or vehicle control before
exposure to 80% O2. After 12 or 24 h, animals were killed, transcardially perfused with PBS, and brain samples were collected in order to perform a fluorometric caspase-3
activity assay. Measurements of hydrolysis of Ac-DEVD-AMC at 460 nm resulted in a highly significant upregulation of caspase-3 activity under hyperoxic conditions, whereas
single treatment with TRP601 significantly decreased caspase-3 activity to control levels after 12 and 24 h. Bars represent mean±S.E.M. (thalamus, n¼ 6/group, normalized
to control animals (21% O2) ***Po0.001, #Po0.05, ###Po0.001, two-way ANOVA). (d) Inhibition of caspase-2 by TRP601 in vivo (1 mg/kg bodyweight i.p.) lead to
decreased protein expression of caspase-2 in thalamus from treated animals, whereas under normoxic conditions TRP601 had no effect. Data are normalized to levels of rat
pups exposed to normoxia (control¼ 100%). Representative western blot images of caspase-2 and b-actin are shown for thalamus. Bars represent mean±S.E.M. (n¼ 8/
group, ***Po0.001, ###Po0.001, one-way ANOVA). (e) Six-day-old Wistar rat pups were either injected with the caspase inhibitor TRP601 (1 mg/kg bodyweight, i.p.) or
vehicle control before exposure to 80% O2. After 12 or 24 h, animals were killed, transcardially perfused with PBS, and brain samples were collected in order to perform a
fluorometric caspase-2 activity assay. Measurements of hydrolysis of VDVAD-AFC at 505 nm resulted in a highly significant upregulation of caspase-2 activity under hyperoxic
conditions, whereas single treatment with TRP601 significantly decreased caspase-2 activity to control levels after 12 and 24 h. Bars represent mean±S.E.M. (thalamus,
n¼ 6/group, normalized to control animals (21% O2) ***Po0.001, ###Po0.001, two-way ANOVA)
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comparable between treated and untreated animals under
normoxic conditions (dashed versus white bar) in both cellular
fractions (Figure 4a).
As cytochrome c forms a complex with Apaf-1 to recruit
caspase-9 and builds up the so-called ‘apoptosome’,13 we
further investigated the effect of TRP601 on the regulation of
Apaf-1 expression under hyperoxic conditions. By western
blot and subsequent densitometric analysis, a highly sig-
nificant upregulation of Apaf-1 protein expression after 12 and
24 h of hyperoxia was shown, decreasing to control levels by a
single administration of TRP601 before hyperoxia. Treatment
with the caspase-2 and -3 inhibitors did not affect Apaf-1
expression under normoxic conditions (Figure 4b).
Hyperoxia results in downregulation of Bcl-2. Members
of the Bcl-2-superfamily are known to be specific regulators
of not only caspase-dependent but also -independent
apoptotic signaling pathways,12 and are shown to be
regulated in neonatal brain injury.9,11 We investigated
whether there are changes in response to hyperoxia in the
expression of the anti-apoptotic protein Bcl-2, and whether
TRP601 has an influence in this experimental setting. As
revealed by quantitative real-time PCR (Figure 5a), 12 and
24 h of hyperoxia caused a significant decrease in Bcl-2
mRNA expression, whereas TRP601 treatment increased
the expression almost to control levels. There was a slight
increase in Bcl-2 mRNA expression under normoxic
conditions (111% versus 101%), which did not reach
statistical significance. The analysis and densitometric
quantification of protein expression detected by
immunoblotting revealed similar regulation patterns but
showed no increase in protein expression of Bcl-2 under
normoxic conditions (Figure 5b).
Hyperoxia triggers (caspase independent) AIF release
into the cytosol. The neuronal cell death program is tightly
regulated and mostly performed by caspases. To check
whether TRP601 functions exclusively through inhibition of
caspase-mediated apoptosis, we further investigated a
caspase-independent apoptosis pathway that is mainly
mediated by AIF.15,16 Therefore, protein expression of AIF
in brain lysates of TRP601 or vehicle-treated pups, which
have been exposed to either 21 or 80% oxygen after
treatment, was measured. Western blot analysis and
quantification of thalamic AIF protein expression revealed a
significant upregulation after hyperoxia, whereas TRP601
administration reversed this effect (Figure 6). The
physiological AIF expression did not change after TRP601
treatment in seven-day-old rat pups under control conditions
(Figure 6, dashed versus white bar).
Figure 3 Elevated oxygen concentrations induce Bid activation. Western blot
from thalamic proteins and subsequent densitometric analysis of full-length Bid
demonstrates a significant downregulation of Bid after hyperoxia (12 or 24 h, black
bars), which is reversed by TRP601 treatment (gray bars, 1 mg/kg, i.p.), TRP601
under room air conditions showed no significant regulation (dashed bar). The
densitometric data represent the ratio of the density of the Bid band to the
corresponding b-actin band. Data are normalized to levels of rat pups exposed to
normoxia (control¼ 100%; bars represent mean±S.E.M., n¼ 7–9/group,
***Po0.001,###Po0.001, one-way ANOVA). Blots are representative of a series
of three blots
Figure 2 TRP601 ameliorates neuronal cell death in vivo. (a) Representative photomicrographs (original magnification  400) of Fluoro-Jade B-stained 10-mm sections
from the thalamus of seven-day-old rats, which were treated without or with TRP601 and were kept under room air (CON) or hyperoxic (24 h) conditions for 24 h.
(b) Quantification of 16 brain regions indicates a highly significant reduction of Fluoro-Jade B-positive degenerated neurons after TRP601 treatment. Bars represent mean
±S.E.M. (n¼ 8–12/group, ***Po0.001, ###Po0.001, one-way ANOVA)
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Discussion
The present study reveals the involvement of caspase-2 in
combination with the intrinsic apoptotic cascade in hyperoxia-
induced injury to the immature central nervous system. We
report for the first time that the inhibitor TRP601 provides
strong evidence for neuroprotective action against hyperoxia-
induced apoptosis influencing intrinsic caspase-dependent
and also caspase-independent pathways. Our results are in
line with a recently published report of a protective effect of
TRP601 in other rodent models of perinatal rodent brain
injury,21 and suggest different potential molecular mechan-
isms that may entertain this tissue-protective effect of
TRP601.
Hyperoxia-induced caspase activation is reduced by
TRP601. To determine the inhibitory capacity and specificity
of TRP601, we first tested TRP601 in vitro. TRP601 and its
active metabolite D2Me-TRP601 are potent inhibitors of
caspase-2 and -3. This correlates with elegant in vitro studies
using VDVAD-based substrates and inhibitors.25,26
Caspase-2 has been recognized as an initiator caspase in
neuronal apoptosis during b-amyloid-mediated toxicity,27
serum deprivation,28 and oxidative stress-induced apoptosis
of neuronal stem cells.29 In our experimental setting,
hyperoxia mediates caspase-2 activation that is reduced by
TRP601. Previous studies in different animal models of
oxygen toxicity4,10,23,30 revealed a significant increase of
effector caspase-3 activity in the brain of oxygen-treated
animals. Treatment with TRP601 highly ameliorates enzy-
matic caspase-3 activity. Our in vivo results suggest that
TRP601 might function upstream of caspase-3; this is
supported by previous reports demonstrating in vitro and
in vivo the inhibition of caspase-3 activity downstream of
caspase-2 modulation with siRNA and caspase-2-deficient
mice.28,31 However, our data do not exclude the possibility
that the TRP601 protective effects might be mediated, at least
in part, through a direct effect of caspase-3.
TRP601 attenuates neuronal cell death in the developing
brain. Exposure of infant rats (P6) to a high oxygen
concentration of 80% over a period of 24 h increased the
rate of cell death in the developing rat brain acutely (see
Figure 2). In previous studies, we demonstrated that
hyperoxia-induced cell death displays morphological
features of physiological apoptotic cell death, occurs in a
Figure 4 TRP601 treatment inhibits hyperoxia-induced intrinsic apoptosis. (a) Western blot analysis from thalamic cytosolic and mitochondrial protein fractions implies a
shift of cytochrome c from mitochondria to the cytosol under hyperoxic conditions that could be prevented by a single TRP601 treatment (1 mg/kg, i.p.). (b) Western blot
analysis of Apaf-1 expression in thalamic brain samples displays a significant upregulation after 12 and 24 h hyperoxia, which was blocked by TRP601. The densitometric data
represent the density ratio of relevant individual bands to the corresponding internal standard band (b-actin or VDAC). Data are normalized to levels of rat pups exposed to
normoxia (control 100%; bars represent mean±S.E.M., n¼ 6/group, ***Po0.001, ###Po0.001, one-way ANOVA compared with respective controls). Blots are
representative of a series of three blots
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disseminated fashion throughout the immature rat brain, is
age dependent, and affects rodents most severely in the first
week of life.23,24 A significant decrease of cell death was
detected when rats were treated intraperitoneally with 1 mg/
kg TRP601 before exposure to high oxygen levels. This
effect indicates possible therapeutic implications of TRP601
in neonatal medicine as a preventive neuroprotective agent.
In line with our results, a neuroprotective effect of apoptosis-
modulating agents has been reported in various in vivo and
in vitro neonatal experimental models.21,31,32
TRP601 inhibits intrinsic apoptotic signaling. Caspase-2
has been shown to induce MOMP that leads to the release of
pro-apoptotic molecules from mitochondria as the release of
cytochrome c.13,18,22 A key step in this mitochondrial intrinsic
pathway of apoptosis is the interaction of members of the
Bcl-2 family to permeabilize the mitochondrial outer
membrane as indicated in several studies.12 To further
elucidate mechanisms involved in the reduction of apoptosis
by TRP601, we visualized cytochrome c and Bcl-2
expression levels after hyperoxia and TRP601 treatment.
Our indirect observation of MOMP as shown by a shift of
cytochrome c from the mitochondrion to the cytosol and a
decrease in full-length Bid coincides with a drastic reduction
of Bcl-2 on mRNA and protein expression. This decrease in
Bcl-2 expression might rearrange the balance between pro-
and anti-apoptotic Bcl-2 family members toward apoptosis,
and trigger the release of cytochrome c most probably by
activation of Bid and consecutive pore-forming ability of Bax
to the outer mitochondrial membrane.33 However, the
underlying mechanism how TRP601 ‘stabilizes’ Bcl-2
expression needs to be clarified by future investigations.
The precise mechanism involved is controversial.
Nonetheless, several models have been proposed in which
Bid and Bcl-2 interact.34,35
Apaf-1 has been described as the core of the apoptosome,
and in the developing brain, Apaf-1 is a death regulator of
neural precursor cells.13,36 Noteworthy, in our model of
oxygen toxicity, Apaf-1 levels increased under hyperoxic
conditions and single TRP601 treatment diminished this
upregulation, and seems to be a part of the protective
mechanism of TRP601. Interestingly, inhibition of Apaf-1
signaling pathway downstream of mitochondrial damage
confers neuroprotection in a rodent model of neonatal
hypoxic–ischemic brain injury.37
Hyperoxia triggers AIF release into the cytosol. Despite
the fact that AIF is proteolytically released from the
Bcl-2 gene expression
Figure 5 TRP601 restores Bcl-2 expression under hyperoxic conditions.
(a) Quantitative analysis of mRNA expression by real-time PCR showed a marked
reduction of Bcl-2 mRNA expression in thalamic samples of rat pups that were kept
for 12 and 24 h under hyperoxia (black bars), whereas TRP601 treatment restores
Bcl-2 expression to control levels (gray bars). Application of TRP601 under room air
(control, dashed bar) showed no significant regulation on Bcl-2 mRNA expression.
(b) The analysis of Bcl-2 protein expression by western blot showed a similar
expression pattern. The protein expression of Bcl-2 is significantly decreased after
12 and 24 h; the single application of TRP601 could restore the Bcl-2 protein
expression almost up to control level. The densitometric data represent the ratio of
the density of the Bcl-2 band to the corresponding b-actin band. Data are
normalized to levels of rat pups exposed to normoxia (control 100%; bars represent
mean±S.E.M., thalamus, n¼ 6–8/group, ***Po0.001, ###Po0.001, one-way
ANOVA compared with respective controls). Blots are representative of a series of
three blots
Figure 6 Caspase-independent hyperoxia-induced apoptosis is regulated by
TRP601 treatment. Densitometric quantification of AIF expression by western
blotting demonstrates a significant upregulation of AIF expression in thalamic
samples of hyperoxia-treated rat pups after 12 and 24 h, which is prevented by
TRP601 treatment. The densitometric data represent the ratio of the density of the
AIF band to the corresponding b-actin band. Data are normalized to levels of rat
pups exposed to normoxia (control 100%; bars represent mean±S.E.M.; n¼ 6/
group, ***Po0.001, ###Po0.001, one-way ANOVA compared with respective
controls). Blots are representative of a series of three blots
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intermitochondrial membrane post-MOMP to the cytoplasm,
once in the cytosol it translocates to the nucleus where it
induces typical features of apoptosis.15,16 However, recently
the existence of a pool of AIF at the outer mitochondrial
membrane (cytosolic site) with the ability to readily
translocate to the nucleus upon excitotoxic stimuli was
demonstrated.38 Here, we showed a significant upregulation
of cytosolic protein expression of mature AIF, which was
totally blocked by a single treatment with TRP601. In vivo
studies consistently demonstrate that AIF targeting has a
large effect on neurons. AIF can be beneficial or harmful for
neurons, depending on physiological settings.39,40
To our knowledge, this is the first report elucidating the
direct effects of neonatal hyperoxia in the developing rat brain,
which specifically focuses on intrinsic apoptosis and investi-
gates a promising neuroprotective substance (TRP601). The
present study shows that caspase-2 has a role upstream of
the mitochondrial pathway, and TRP601 can prevent MOMP.
Our data suggest that caspase-2 and -3 may be therapeutic
targets to limit neurodegeneration resulting from hyperoxia-
induced injury in the developing brain. Our findings are highly
relevant from a clinical perspective because oxygen admin-
istration to neonates is often inevitable and candidates for
adjunctive neuroprotective therapies are still missing.
Materials and Methods
Preparation of drug solutions. For in vitro studies, TRP601
(C40H48F2N6O11; MW: 826.84; Chiesi, Parma, Italy) and D2Me-TRP601
(C38H44F2N6O11; MW: 798.79) were initially solubilized in 100% DMSO. The final
concentration of DMSO was r10%. For in vivo experiments, TRP601 was
formulated in 0.9% NaCl containing 0.1% DMSO for intraperitoneal (i.p.)
administration, an appropriate vehicle control (0.1% DMSO in 0.9% NaCl) was
used for control animals as indicated.
In vitro enzyme kinetics. Kinetics experiments were done according to the
continuous method. Assays of chromogenic substrate cleavage contained in 100ml
caspase buffer (20 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA),
58.5 ng of human active recombinant caspase-2 (Biomol, Plymouth, MN, USA) or
20 ng of human active recombinant caspase-3 (Sigma, Saint Louis, MO, USA), and
100mM of chromogenic substrate (Ac-DEVD-pNA for caspase-3 and Ac-VDVAD-
pNA for caspase-2) in the presence of a range of concentrations of TRP601 or
D2ME-TRP601. For caspase-2 assays, buffer was supplemented with 1 M
succinate. Cleavage of the chromogenic substrate as a function of time was
monitored at 405 nm, and the initial velocity (V0) was determined from the linear
portion of the progress curve. The formation of para-nitroaniline (pNA) was followed
every 30 s for 150 min at 37 1C with a microtiter plate reader (Paradigm Multi-Mode
Microplate Detection Platform, SoftMax Pro 5.2 software; Molecular Devices,
St. Gre´goire, France). V0, relative velocities, Km, and IC50 were determined from
experimental data using GraphPad Prism 5.01 software program (GraphPad
Software, La Jolla, CA, USA). Standard deviations of the reported values were
below 10%.
Animal experiments. Six-day-old Wistar rats (Charite´-Universita¨tsmedizin
Berlin) were randomly assigned to four groups and treated as follows: (1) normoxia
(21% O2) and vehicle i.p. injections, (2) normoxia and 1 mg TRP601/kg i.p.
injections, (3) hyperoxia (80% O2) and vehicle i.p. injections, and (4) hyperoxia and
1 mg TRP601/kg i.p. injections. For hyperoxia or normoxia exposure, pups were
kept with their dams. In all study groups, TRP601 or vehicle was injected at the
beginning of an oxygen/room air exposure.
Animal experiments were performed according to institutional guidelines of the
Charite´-Universita¨tsmedizin Berlin.
Tissue preparation. At 12 and 24 h after treatment initiation, postnatal day-6
(P6) Wistar rat pups were killed with chloral hydrate (1 mg/kg, i.p.). For histological
analysis, P6 Wistar rat pups (n¼ 6 per group) were transcardially perfused with
heparinized 0.01 M phosphate-buffered saline at pH 7.4, subsequently with 4%
paraformaldehyde at pH 7.4, and decapitated. Brains were removed, the
cerebellum and the olfactory bulb discarded. After a postfixation time of 3 days at
4 1C, brains were embedded in paraffin and processed for Fluoro-Jade B staining.
For molecular studies, P6 Wistar rat pups (n¼ 6–10 per group) were transcardially
perfused with normal saline solution and decapitated. Brain tissue was
microdissected from the retrosplenial cortex and thalamus, snap frozen in liquid
nitrogen, and stored at 80 1C.
Fluoro-JadeB staining and quantitation of neurodegeneration in
different brain regions. Paraffin sections (10 mm) were stained with Fluoro-
Jade B, and degenerating cells were determined in the frontal, parietal, cingulate,
retrosplenial cortex, caudate nucleus, corpus callosum and adjacent white matter,
thalamus, hippocampal dentate gyrus, and subiculum by means of a stereological
dissector estimating mean numerical cell densities of degenerating cells as
described previously.3
Quantitative real-time PCR. Total cellular RNA was isolated from snap-
frozen tissue by acidic phenol/chloroform extraction and reverse transcribed. The
resulting cDNA was amplified by real-time PCR. Real-time PCR for Bcl-2 was
performed in triplicates for each sample using 20 Assays-on-Demand Gene
Expression Assay Mix (Applied Biosystems, Foster City, CA, USA) and 30 ng of
cDNA template. For hypoxanthine-guanine phosphoribosyltransferase (HPRT), the
PCR reaction was carried out with 150 pg cDNA. The expression of Bcl-2 and HPRT
was analyzed with the ABI Prism 7500 sequence detection system (Applied
Biosystems) according to standard 2DDCt method.
Immunoblotting. Western blot analysis was performed as published
elsewhere,3 with minor adaptations. Briefly, nitrocellulose membranes were
incubated overnight at 4 1C with rabbit polyclonal anti-caspase-2 (18 kDa; 1 : 200;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-cytochrome c (12.6 kDa;
1 : 1.000; BioVision, Mountain View, CA, USA), anti-Apaf-1 (135 kDa; 1 : 500; New
England Biolabs, Frankfurt, Germany), anti-Bid (22 kDa; 1 : 1.000; Millipore,
Schwalbach, Germany), or anti-AIF (57 kDa; 1 : 500; New England Biolabs).
Secondary incubations were performed with horseradish peroxidase-linked anti-
rabbit antibody (1 : 5.000; Amersham Biosciences, Bucks, UK). Positive signals
were visualized using enhanced chemiluminescence (Amersham Biosciences) and
quantified using a ChemiDoc XRSþ system and the software Quantity One (Bio-
Rad, Munich, Germany). Membranes were stripped, then washed, blocked, and
reprobed overnight at 4 1C with mouse anti-b-actin monoclonal antibody (42 kDa;
1 : 10.000; Sigma-Aldrich, Taufkirchen, Germany) or anti-voltage-dependent anion
channel (VDAC) polyclonal antibody (32 kDa; 1 : 1.000; New England Biolabs).
Measurement of caspase-2 and -3 enzymatic activities. Caspase-2
and -3 activities were measured using fluorometric assay kits (BioVision and
Sigma-Aldrich). Protein samples were prepared as described for western blotting by
using the lysis buffer of the kit, and the samples were incubated with the fluoro-
genic substrates VDVAD-AFC (caspase-2) or Ac-DEVD-AMC (caspase-3). The
enzymatic activity was measured using an Infinite M200 fluorescent plate reader
(Tecan, Salzburg, Austria).
Statistical analyses. Data were analyzed using the R Project for Statistical
Computing (Statistics Department of the University of Auckland, Auckland, New
Zealand) and presented as mean±standard error. Group effects were assessed by
analysis of variance (ANOVA), followed by post hoc independent sample t-test
multiple comparison. P-values are presented after Bonferroni correction. Adjusted
P-values ofo0.05 were considered statistically significant.
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